Literature DB >> 24762323

Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts.

S Zafar1, D E Coates, M P Cullinan, B K Drummond, T Milne, G J Seymour.   

Abstract

The mevalonate pathway (MVP) and the anti-angiogenic effect of bisphosphonates have been shown to play a role in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). This study determined the effect of the bisphosphonate, zoledronic acid and the replenishment of the MVP by geranylgeraniol on human gingival fibroblasts. Cell viability, apoptosis, morphological analysis using transmission electron microscopy, and gene expression for vascular endothelial growth factor A, bone morphogenic protein 2, ras homologue gene family member B, epiregulin and interferon-alpha were conducted. Results showed cellular viability was decreased in the presence of zoledronic acid and the co-addition of zoledronic acid with geranylgeraniol restored cell viability to control levels. Caspase 3/7 was detected in zoledronic-acid-treated cells indicating apoptosis. Transmission electron microscopy revealed dilation of the rough endoplasmic reticulum with zoledronic acid and the appearance of multiple lipid-like vesicles following the addition of geranylgeraniol. Zoledronic acid significantly (P < 0.05, FR > ± 2) up-regulated vascular endothelial growth factor A, bone morphogenic protein 2, ras homologue gene family member B and epiregulin at one or more time points but not interferon-alpha. Addition of geranylgeraniol resulted in a reduction in the expression of all five genes compared with zoledronic-acid-treated human gingival fibroblasts. The study concluded geranylgeraniol partially reversed the effects of zoledronic acid in human gingival fibroblasts both at the cellular and genetic levels, suggesting the regulation of these genes is mediated via the mevalonate pathway.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bisphosphonate-related osteonecrosis of the jaw; geranylgeraniol; human gingival fibroblasts; mevalonate pathway; zoledronic acid

Mesh:

Substances:

Year:  2014        PMID: 24762323     DOI: 10.1111/jop.12181

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  16 in total

1.  Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws.

Authors:  Elisabetta Merigo; Luigi Cella; Aldo Oppici; Maria Cristina Arbasi; Fabio Clini; Matteo Fontana; Carlo Fornaini
Journal:  J Lasers Med Sci       Date:  2018-03-20

Review 2.  Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.

Authors:  Sherry S Agabiti; Yilan Liang; Andrew J Wiemer
Journal:  Mol Membr Biol       Date:  2016-08-18       Impact factor: 2.857

3.  Wound healing protein profiles in the postoperative exudate of bisphosphonate-related osteonecrosis of mandible.

Authors:  Soung Min Kim; Mi Young Eo; Yun Ju Cho; Yeon Sook Kim; Suk Keun Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-24       Impact factor: 2.503

4.  In vitro Effect of Geranylgeraniol (GGOH) on Bisphosphonate-Induced Cytotoxicity of Oral Mucosa Cells.

Authors:  Krit Rattanawonsakul; George Bullock; Robert Bolt; Frederik Claeyssens; Simon Atkins; Vanessa Hearnden
Journal:  Front Oral Health       Date:  2022-06-20

5.  Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts.

Authors:  S Zafar; D E Coates; M P Cullinan; B K Drummond; T Milne; G J Seymour
Journal:  Clin Oral Investig       Date:  2016-01-22       Impact factor: 3.573

6.  Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics.

Authors:  Jee-Hwan Kim; Yong Jae Ko; Ji-young Kim; Yoonsoo Oh; Jihye Hwang; Sangjin Han; Sanguk Kim; Jae-Hoon Lee; Dong-Hoo Han
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

7.  KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

Authors:  István Kenessey; Krisztina Kói; Orsolya Horváth; Mihály Cserepes; Dávid Molnár; Vera Izsák; Judit Dobos; Balázs Hegedűs; József Tóvári; József Tímár
Journal:  Oncotarget       Date:  2016-11-29

8.  Synthetic Calcium Phosphate Ceramics as a Potential Treatment for Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Siri Paulo; Mafalda Laranjo; Ana M Abrantes; João Casalta-Lopes; Kathleen Santos; Ana C Gonçalves; Anabela Baptista Paula; Carlos Miguel Marto; Ana Bela Sarmento-Ribeiro; Eunice Carrilho; Arménio Serra; Maria F Botelho; Manuel M Ferreira
Journal:  Materials (Basel)       Date:  2019-06-06       Impact factor: 3.623

Review 9.  Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.

Authors:  Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich
Journal:  J Int Med Res       Date:  2018-08-09       Impact factor: 1.671

10.  Application of Autologous Platelet-Rich Plasma on Tooth Extraction Site Prevents Occurence of Medication-Related Osteonecrosis of the Jaws in Rats.

Authors:  Luan Felipe Toro; João Martins de Mello-Neto; Fernanda Furuse Ventura Dos Santos; Letícia Chaves Ferreira; Cristian Statkievicz; Luciano Tavares Ângelo Cintra; João Paulo Mardegan Issa; Rita Cássia Menegati Dornelles; Juliano Milanezi de Almeida; Maria José Hitomi Nagata; Valdir Gouveia Garcia; Leticia Helena Theodoro; Cláudio Aparecido Casatti; Edilson Ervolino
Journal:  Sci Rep       Date:  2019-01-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.